{
  "created_at": "Sat Dec 18 6:54:19 +0000 2021",
  "id_str": "1471941406788931589",
  "full_text": "Pfizer pushed back plans to seek authorization of its Covid vaccine in children 2 to 5 years old, after a weaker-than-expected immune response in a study https://t.co/tMYNYMwXdq",
  "display_text_range": [
    0,
    177
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/tMYNYMwXdq",
        "expanded_url": "https://on.wsj.com/3yD79MB",
        "display_url": "on.wsj.com/3yD79MB",
        "indices": [
          154,
          177
        ]
      }
    ]
  },
  "user": {
    "name": "The Wall Street Journal",
    "screen_name": "WSJ",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/971415515754266624/zCX0q9d5_normal.jpg"
  },
  "retweet_count": 37,
  "favorite_count": 78,
  "possibly_sensitive": false,
  "original_created_at": "Fri Dec 17 20:32:33 +0000 2021",
  "localize": [
    {
      "locale": "ja",
      "full_text": "ファイザーは、2～5歳の小児を対象とした同社のワクチン「コビット」の試験で、免疫反応が予想より弱かったことを受け、認可を求める計画を延期した https://t.co/tMYNYMwXdq"
    },
    {
      "locale": "zh",
      "full_text": "辉瑞公司推迟了其Covid疫苗在2至5岁儿童中的授权计划，因为在一项研究中，其免疫反应弱于预期https://t.co/tMYNYMwXdq。"
    },
    {
      "locale": "zh-Hant",
      "full_text": "輝瑞公司推遲了其Covid疫苗在2至5歲兒童中的授權計劃，因爲在一項研究中，其免疫反應弱於預期https://t.co/tMYNYMwXdq。"
    }
  ]
}